高级检索
当前位置: 首页 > 详情页

Alpha-fetoprotein-to-PIVKA-II ratio as a potential biomarker for hepatocellular carcinoma differentiation, imaging characteristics, and patient survival

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
出处:
ISSN:

关键词: Alpha-fetoprotein-to-PIVKA-II ratio (APR) hepatocellular carcinoma (HCC) immunohistochemical differentiation imaging characteristics survival

摘要:
Alpha-fetoprotein-to-PIVKA-II ratio (APR) may serve as a new marker to predict the grade of differentiation, imaging characteristics, and prognosis of hepatocellular carcinoma (HCC). This study aimed to demonstrate the prognostic significance of high APR for poorly differentiated HCC (PD-HCC), imaging characteristics and overall survival (OS) in patients after intra-arterial therapies.Receiver operating characteristic (ROC) curves were constructed and areas under the curve (AUCs) were calculated to evaluate the predictive ability of APR to discriminate subgroup(s) of HCC with good or poor prognosis. Kaplan-Meier survival analysis was performed to evaluate the effect of tumor differentiation and change in APR on overall patient survival.The cut-off value of APR used in the diagnostic setting was 0.175. Almost all patients in the PD-HCC group (90.9%) had a high APR value, while 100% and 84.2% of well-differentiated and moderately differentiated HCC (WD-HCC and MD-HCC) patients, respectively, had a low APR value (P<0.001). APR had a high sensitivity (91%) and specificity (90%) in differentiating PD-HCCs from WD-HCCs/MD-HCCs (P<0.001). Patients with high APR tended to have large and multiple tumors, vascular invasion and high percentage signal ratio (PSR). OS was slightly shorter in the PD-HCC group and in the high (>0.175) APR group.This study showed that patients with high APR and those with PD-HCC had a worse prognosis, and APR could be an important non-invasive biomarker for predicting the degree of tumor differentiation, imaging characteristics and patient prognosis.2024 AME Publishing Company. All rights reserved.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Medical Imaging, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:56916 今日访问量:2 总访问量:1772 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)